What Myolex does

Myolex Inc. is a privately held, Brookline, Massachusetts-based medical technology company that has developed and commercialized a non-invasive muscle assessment platform based on Electrical Impedance Myography (EIM). The core product, the mScan research device, passes a high-frequency, imperceptible electrical current through muscle tissue via surface electrodes and measures resistance, reactance, phase, frequency dependence, and anisotropy across multiple frequencies to characterize muscle composition and micro-architecture. The device is paired with a proprietary data analytics platform that applies deep learning to impedance datasets to predict myofiber size, fiber distribution, and disease progression, with internal claims of "virtual biopsy"-grade concordance with histological observations. The system is positioned as a painless, portable, at-home-capable alternative to MRI for single-muscle assessment, with applications in tracking disease progression and treatment response in neuromuscular disorders (ALS, DMD), muscle wasting conditions including sarcopenia, and monitoring lean-mass loss in patients on GLP-1 obesity drugs.

Myolex's go-to-market is sales-led and targets three primary customer segments: (1) pharmaceutical companies conducting clinical trials in neuromuscular and muscle wasting diseases, who can use EIM as a sensitive biomarker to reduce trial sample sizes and timelines; (2) academic medical centers and clinical researchers studying neuromuscular disease; and (3) emerging use in monitoring muscle loss among patients on GLP-1 therapies. The company sells directly through enterprise sales inquiries via its website and phone, with quote-based, multi-year contract pricing that is not publicly disclosed. The product is currently positioned as "Available Today for Clinical Research," meaning it is sold for research-use only and has not yet received FDA clearance as a clinical diagnostic; the company's marketing material explicitly conditions MRI-replacement and clinical claims on future FDA approval.

The company is sub-scale (1-10 employees) and venture-backed, with disclosed investors including Caerus Ventures, Nautilus Venture Partners, and non-dilutive funding from NIH (NIAMS and NINDS, including Phase 2B SBIR). The most recent disclosed capital event is a $2.2 million NIH/NIAMS grant awarded in August 2024 to validate EIM as an MRI alternative and further develop predictive algorithms. The technology is backed by 10 issued patents plus 2 pending applications, over 170 peer-reviewed publications, and 10+ pharmaceutical-company-supported clinical studies. The company was co-founded by Dr. Seward Rutkove, who developed the core EIM technology at Harvard Medical School and Beth Israel Deaconess Medical Center.

Name

Myolex

Legal name

Myolex Inc.

Website

https://myolex.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE)

akta.pro secondary industry

Sensor Fusion, Interface ICs & Modules (AFE/Readout/Packaging/Calibration) (HDAHALAO)

Keywords

• Muscle assessment devices
• Electrical impedance myography
• Neuromuscular diagnostics
• Clinical research devices
• Muscle wasting monitoring

Headquarters

HQ city

Brookline

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. mScan Research Device Sales: Myolex sells its mScan research device to pharmaceutical companies, clinical research institutions, and healthcare providers for use in clinical trials and muscle assessment studies. The device is currently available for clinical research purposes.
2. Data Analytics Platform: The company provides a data analytics platform alongside the mScan device, likely offered as a subscription or included service for data interpretation and clinical trial support.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Myolex develops and sells the mScan research device based on proprietary Electrical Impedance Myography (EIM) technology. The device non-invasively measures individual muscle composition and micro-infrastructure by passing a weak electrical current through muscle tissue and analyzing impedance characteristics across multiple frequencies. The product is sold for clinical research use to pharmaceutical companies conducting neuromuscular disease trials (ALS, DMD) and academic medical centers, with an accompanying data analytics platform for measurement interpretation.

Product overview

Myolex offers a unified product ecosystem centered on electrical impedance myography (EIM) technology for muscle assessment. The core offering is the Myolex mScan research device, which combines specialized hardware electrodes with an integrated data analytics platform to provide comprehensive, non-invasive muscle condition monitoring. The system is designed for clinical research use and enables both in-clinic and at-home muscle measurements.

Differentiator

Problem solved

Functional benefit

Brands

• mScan: The Myolex mScan research device and data analytics platform is the first quantitative, comprehensive, sensitive, consistently reproducible, painless, and portable device that can be used to monitor and display the bioimpedance of muscle.

Products and services

• Myolex mScan A quantitative, painless, and portable research device that monitors and displays muscle bioimpedance at the individual or small group of muscle level by measuring holistic changes in muscle composition and micro-infrastructure using Electrical Impedance Myography (EIM). Designed for clinical research use in neuromuscular disease trials (ALS, DMD), academic research studies, and at-home patient monitoring, including GLP-1 muscle wasting monitoring. Includes an accompanying data analytics platform for measurement interpretation.

Quantifiable outcome

• Daily at-home measurements demonstrated 10X improvement over monthly measurements in terms of reductions in sample size
• +3 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature6 records

Partnerships

Three partnerships are on record, tiered core and minor.

• ALSA (Amyotrophic Lateral Sclerosis Association)coreStrategic or Co-development PartnerALSA-funded studies demonstrating EIM's substantial sensitivity to ALS disease status in mice and humans, and significant correlation between decline in 50 kHz phase value and ALS patient survival.
• Beth Israel Deaconess Medical Center / Harvard Medical SchoolcoreStrategic or Co-development PartnerAcademic medical center where co-founder Dr. Seward Rutkove developed the core EIM technology. Dr. Rutkove serves as Nancy Lurie Marks Chair of Neurology at BIDMC and Professor of Neurology at Harvard Medical School.
• Barrow Neurological InstituteminorStrategic or Co-development PartnerClinical research partner that collected data demonstrating mScan's excellent reproducibility and reliability across ALS patients with only limited training.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• FIGUR8: FIGUR8 is the most direct competitor: a digital MSK biomarker and AI-driven muscle assessment platform sold to clinicians, researchers, and biopharma, overlapping directly with Myolex's EIM-based neuromuscular biomarker offering. Notably, FIGUR8's CEO Nan-Wei Gong also serves on Myolex's advisory board, underscoring the close technical and market overlap.
• ImpediMed: ImpediMed commercializes bioimpedance spectroscopy devices for fluid status and body composition in clinical settings, competing head-on with Myolex on bioimpedance hardware, clinical workflow integration, and reimbursement pathways. Both companies target pharma and clinical use cases where impedance-derived biomarkers drive trial or treatment decisions.
• InBody: InBody is a leading global bioimpedance body-composition analyzer used in clinics, research, and increasingly in GLP-1 and sarcopenia settings. It is a direct alternative to mScan for any quantitative muscle/body composition measurement, with much broader geographic reach and a stronger consumer brand.
• Delsys (Artinis Medical Systems): Artinis (owner of Delsys) is a primary manufacturer of surface EMG and bioimpedance sensors used in neuromuscular research, rehabilitation, and sports. It overlaps directly with Myolex in neuromuscular assessment research tools sold to academic and clinical labs.

Broad incumbents

• Clario: Clario is a large clinical-trial technology and eCOA/imaging vendor serving pharma, including outcome assessments in neuromuscular trials. It competes for the same pharma trial endpoints and biomarker-decision budgets that Myolex targets, but as a broad incumbent across many therapeutic areas.
• Medidata (Dassault Systèmes): Medidata provides the dominant clinical trial data capture and analytics platform used by pharma, including in ALS and DMD. It is a broad incumbent that could integrate competing biomarkers or partner with Myolex, shaping how EIM data is collected and used in trials.

Emerging players

• Empatica: Empatica builds FDA-cleared wearable sensors and digital biomarkers for neurological and rare disease conditions, with strong pharma trial partnerships. It overlaps with Myolex in at-home, patient-led neuromuscular/cNS monitoring for clinical research, but focuses on broader wearable signals rather than muscle impedance.
• MindMaze: MindMaze develops digital neuro-assessment and rehabilitation tools with biomarkers for stroke and neurodegenerative disease. It overlaps with Myolex in digital neurological biomarker assessment for clinical research and trials, with stronger human-machine interface and rehab positioning.
• NX Prenatal: NX Prenatal is an emerging maternal-fetal biomarker developer with a similar profile of small team, deep IP, and clinical validation in a niche indication. It is comparable to Myolex as a similarly staged private medical biomarker company pursuing regulatory clearance and pharma partnerships.

Regional players

• Bioventus: Bioventus is an established orthopedic and muscle health medical device company selling point-of-care tools and orthobiologics. It is comparable to Myolex in the broader muscle health/sarcopenia end market, though it does not currently offer an EIM-equivalent biomarker and is more focused on surgical recovery than neuromuscular disease.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/myolex

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Myolex